Über das Unternehmen
Currently approved and clinical blood stem cell therapies rely on editing cells outside the body (ex-vivo). This involves extracting stem cells from the patient, editing them individually at specialized manufacturing facilities, administering high-dose chemotherapy to destroy existing bone marrow, and then transplanting the corrected cells back. The process is inherently unscalable, toxic, and lengthy, often taking six months to a year. At Immitra Bio, we are developing a novel in-vivo gene editing platform that reduces treatment time from months to days, eliminates the need for chemotherapy, and is delivered as an off-the-shelf drug that all patients with the same condition can receive. Our therapy enables safe, fast, and truly scalable approach to gene correction.